Antibody persistence and immunological memory at age 4 years after meningococcal group c conjugate vaccination in children in the united kingdom

Journal of Infectious Diseases

Volumn 186, Issue 9, 2002, Pages 1353-1357

  Borrow, Ray ^a   Goldblatt, David ^b   Andrews, Nick ^c   Southern, Jo ^c   Ashton, Lindsey ^b   Deane, Sarah ^a   Morris, Rhonwen ^d   Cartwright, Keith ^d   Miller, Elizabeth ^c  

^a WITHINGTON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; MENINGIVAC; MENINGOCOCCUS VACCINE; POLYSACCHARIDE;

ANTIBODY TITER; ARTICLE; CHILD; DRUG CONJUGATION; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; IMMUNE SYSTEM; IMMUNOLOGICAL MEMORY; INFANT; PRIORITY JOURNAL; SIDE EFFECT; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CHILD; CHILD, PRESCHOOL; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; TIME FACTORS; VACCINES, CONJUGATE;

EID: 0036838274     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/344324     Document Type: Article

References (13)

1. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: A success story. Vaccine 2001; 20(Suppl 1):S58-67.
2. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: A re-evaluation of correlates of protection. Infect Immun 2001; 69:1568-73.
3. Richmond PC, Borrow R, Miller E, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999; 179:1569-72.
4. Campagne G, Garba A, Fabre P, et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000; 19:144-50.
5. Ahman H, Kayhty H, Vuorela A, Leroy O, Eskola J. Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid. Vaccine 1999; 17:2726-32.
6. Richmond P, Goldblatt D, Fusco PC, et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 1999; 18:641-6.
7. Borrow R, Goldblatt D, Andrews N, Richmond P, Southern J, Miller E. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory following meningococcal C conjugate vaccination in young children. J Infect Dis 2001; 184:377-80.
8. Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183:160-3.
9. Joseph H, Miller E, Dawson M, Andrews N, Feavers I, Borrow R. Meningococcal serogroup A avidity indices as a surrogate marker of priming for the induction of immunologic memory after vaccination with a meningococcal A/C conjugate vaccine in infants in the United Kingdom. J Infect Dis 2001; 184:661-2.
10. Goldblatt D, Pinto Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998; 177:1112-5.
11. Anttila M, Eskola J, Ahman H, Kayhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998; 177:1614-21.
12. MacLennan J, Obaro S, Deeks J, et al. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis 2001; 183:97-104.
13. McVernon J, MacLennan J, Buttery J, Oster P, Danzig L, Moxon ER. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J 2002; 21:747-53.